AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Key facts
- Who runs it
- Idoven 1903 S.L.
- Where
- Netherlands and Spain13 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 5,342 people, planned
- Started
- 4 Apr 2023
- Expected to end
- Dec 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- AI-powered ECG analysis to detect cardiac arrhythmic episodes
- Record updated
- 6 November 2026
Who can take part
- Age
- 4 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patient presenting relevant cardiac arrhythmias and cardiac patterns (including supraventricular tachycardias, abnormal ECG patterns, ventricular tachycardias, ventricular fibrillation, pulseless electrical activity or asystole among others) that have been recorded with at least one short-term ECG medical device according to guidelines with ≥1 signal-channel
- Patient with suspected or diagnosed acute/chronic cardiac diseases (including patients with heart failure, patients with history of cardiac arrhythmias, patients with probable coronary artery diseases, patients with cardiomyopathies, patients with pacemakers or implantable cardioverter-defibrillators (ICD), patients with indication of pacemaker or ICD in current or short-term phase, patients participating in other interventional clinical investigation, patients with hemodynamic instability or acute coronary syndromes, pregnant patients, patients with cancer and chemotherapy, patients with life-expectancy lower than 24 months, patients with in or out-of-hospital cardiac arrest with ventricular fibrillation as first documented rhythm)
- At least one ECG tracing that can be exported in raw data
- Signed informed consent. Patients unable to consent, it will be requested to an authorized relative
Who cannot take part
- Unwillingness or inability to sign study written informed consent
- Unavailable or suboptimal quality of the electrocardiographic signal in raw data
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
WILLEM is a multi-center, prospective and retrospective cohort study.
Read full original descriptionShow less
The study will assess the performance of a cloud-based and AI-powered ECG analysis platform, named Willem™, developed to detect arrhythmias and other abnormal cardiac patterns. The main questions it aims to answer are:
1. A new AI-powered ECG analysis platform can automatice the classification and prediction of cardiac arrhythmic episodes at a cardiologist level. 2. This AI-powered ECG analysis can delay or even avoid harmful therapies and severe cardiac adverse events such as sudden death.
The prerequisites for inclusion of patients will be the availability of at least one ECG record in raw data, along with patient clinical data and evolution data after more than 1-year follow-up.
Cardiac electrical signals from multiple medical devices will be collected by cardiology experts after obtaining the informed consent. Every cardiac electrical signal from every subject will be reviewed by a board-certified cardiologist to label the arrhythmias and patterns recorded in those tracings. In order to obtain tracings of relevant information, >95% of the subjects enrolled will have rhythm disorders or abnormal ECG's patterns at the time of enrollment.
The 2 groups in the trial
- Train group
Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record \>10 sec in raw data will be used to design new methodologies and algorithms for cardiac patterns recognition.
Treatment: AI-powered ECG analysis to detect cardiac arrhythmic episodes
- Test group
Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record \>10 sec in raw data will be used to evaluate performance of methodologies aiming to avoid overfitting. Every 10 patients included in Train group; a new patient is included in the test group.
Treatment: AI-powered ECG analysis to detect cardiac arrhythmic episodes
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Electrocardiographic Data From High-risk Cardiac Patients Using Willem™ Cardiologist-level Artificial Intelligence Software. WILLEM Trial.
- Record updated
- 6 November 2026